Phase 2 Clinical Trial For SPMS With Intranasal Monoclonal A

Tiziana Life Sciences expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis that’s administered through the nose.

Related Keywords

, Tiziana Life Sciences , Secondary Progressive Multiple Sclerosis , Emission Tomography , Modified Fatigue Impact Scale , Expanded Disability Status Scale , Foot Walk Test , Neuroqol Fatigue ,